BioMarin and Sarepta bicker over DMD data; Kite gets a head start on CAR-T pricing talk;

@FierceBiotech: J&J gets $116M to help hustle along new Ebola vaccine. Article | Follow @FierceBiotech

@JohnCFierce: We are slowly ramping up Asia reporting this month ahead of FiercePharmaAsia launch in Feb. Good time to start sending embargoed news my way. | Follow @JohnCFierce

@DamianFierce: $ENTA gets $50M for EU approval of $ABBV's hep C combo. From #JPM15, here's what they're going to do with it. More | Follow @DamianFierce

> At this week's JP Morgan Healthcare Conference, BioMarin ($BMRN) CEO Jean-Jacques Bienaime touted the Duchenne muscular dystrophy-treating drisapersen, acquired in its buyout of Prosensa, as superior to a rival drug from Sarepta ($SRPT), sparking a testy exchange between the two companies. Story

> Kite Pharma ($KITE), a contender in the novel space of CAR-T therapies for cancer, says its early-stage candidate could sell for $150,000 per treatment once it hits the market, undercutting analyst expectations for the class of drugs. More

> AbbVie's ($ABBV) combination hepatitis C treatment won European approval, triggering a $50 million payout for partner Enanta Pharmaceuticals ($ENTA). News

Medical Device News

@FierceMedDev: FDA, CDC investigating death, illnesses from IV bags intended for training. News | Follow @FierceMedDev

@VarunSaxena2: J&J says fishy phone calls recruiting women to file vaginal mesh-related suits warrant an investigation. More | Follow @VarunSaxena2

@EmilyWFierce: Gilead blazes ahead in hep C pricing battle with two new PBM deals. Report | Follow @EmilyWFierce

> Bill introduced in Congress to simplify marketing of research use only devices and diagnostics. Story

> Medical device, diagnostic venture investment at $2.7B, highest since 2008. More

Pharma News

@FiercePharma: Boehringer mulls sale of generic plant as stateside shakeup continues. More | Follow @FiercePharma

@CarlyHFierce: With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics. Article | Follow @CarlyHFierce

> Gilead blazes ahead in hep C pricing battle with two new PBM deals. More

> Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.